Free Research Report as Tesaro’s Revenue Rocketed 740%

Stock Monitor: Ohr Pharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / December 21, 2017 / Active-Investors.com has just released a free earnings report on Tesaro, Inc. (NASDAQ: TSRO). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=TSRO . The Company reported its third quarter fiscal 2017 operating results on November 07, 2017. The biopharmaceutical Company’s net loss narrowed on a y-o-y basis, while it surpassed top- and bottom-line expectations. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Ohr Pharmaceutical, Inc. (NASDAQ: OHRP), which also belongs to the Healthcare sector as the Company Tesaro. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=OHRP

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Tesaro most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=TSRO

Earnings Highlights and Summary

Tesaro reported total revenues of $142.8 million for Q3 2017 compared to $17.0 million for Q3 2016. The Company’s revenue numbers exceeded analysts’ expectations of $121.3 million.

During Q3 2017, Tesaro’s cost of sales totaled $7.5 million, and included $6.2 million associated with product revenue, and $1.3 million related to amortization of milestones recorded upon the US Food and Drug Administration (FDA)’s approval of ZEJULA and first commercial sales of VARUBI/VARUBY in the US and Europe. The Company’s cost of sales totaled $0.8 million for Q3 2016.

Tesaro’s research and development (R&D) expenses increased to $73.4 million for Q3 2017 compared to $60.8 million for Q3 2016, driven primarily by an increased headcount, the advancement of the Company’s earlier-stage immuno-oncology portfolio, and the expansion of the TSR-042 and TSR-022 programs.

For Q3 2017, Tesaro’s selling, general, and administrative expenses (SG&A) increased to $84.0 million compared to $37.7 million for Q3 2016, primarily due to an increased headcount, activities in support of the launches of ZEJULA and VARUBY in the US and Europe, and higher professional service fees.

Tesaro’s net loss totaled $25.3 million, or $0.47 per share, for Q3 2017 compared to a net loss of $87.9 million, or $1.72 per share, for Q3 2016. The Company’s loss was lower than Wall Street’s estimates of $1.04 per share.

Segment Results

During Q3 2017, Tesaro’s net product revenue totaled $41.8 million compared to $1.3 million for Q3 2016. The growth was driven by the continued strong launch of ZEJULA in the US. ZEJULA’s net revenue totaled $39.4 million, while VARUBI/VARUBY’s revenues totaled $2.4 million compared to $1.3 million for Q3 2016.

In the reported quarter, approximately 65% of prescriptions were filled through Tesaro’s specialty pharmacy channel and the remainder were filled by specialty distributors.

For Q3 2017, Tesaro’s license, collaboration, and other revenue totaled $101.0 million, and included the $100.0 million up-front payment received as part of the license agreement with Takeda. This compares to license, collaboration, and other revenue of $15.7 million for Q3 2016, which included the majority of the $15.0 million up-front payment received as part of the Zai Lab license agreement.

Recent Business Developments

On October 25, 2017, the FDA approved the intravenous (IV) formulation of VARUBI® (rolapitant), and the US commercial launch was planned for November. The unit demand for VARUBI oral capsules increased 74% on a y-o-y basis for Q3 2017 as the brand continues to penetrate the US oral NK-1 market.

Tesaro initiated clinical trials to support the planned Phase-3 studies of niraparib combined with its anti-PD-1 antibody, TSR-042, in patients with lung and ovarian cancers and to evaluate niraparib plus TSR-042 in patients with advanced or metastatic cancers suitable for treatment with an anti-PD-1 antibody, including ovarian and lung.

Cash Matters

As of September 30, 2017, Tesaro had approximately $521.3 million in cash and cash equivalents, and approximately 54.4 million outstanding shares of common stock.

Stock Performance Snapshot

December 20, 2017 – At Wednesday’s closing bell, Tesaro’s stock slightly declined 0.69%, ending the trading session at $76.37.

Volume traded for the day: 554.48 thousand shares.

After yesterday’s close, Tesaro’s market cap was at $4.32 billion.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484746